Low Level FLT3LG is a Novel Poor Prognostic Biomarker for Cervical Cancer with Immune Infiltration

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2022 Oct 24

PMID 36274829

Authors

Lihua Chen

Yuxuan Huang

Binhua Dong

Yu Gu

Ye Li

Wei Cang

Pengming Sun

Yang Xiang

Affiliations

Soon will be listed here.

Abstract

Introduction: The FMS-related tyrosine kinase 3 (FLT3) ligand (FLT3LG), a growth factor, binds to FLT3 on dendritic cell (DCs) to enhance their differentiation and expansion. It has shown great potential as an immunotherapy target for cancers. However, the expression and function of FLT3LG in cervical cancer remain largely unknown.

Materials And Methods: In this study, we obtained the expression of FLT3LG, the clinical prognosis in cervical cancer, via multiple databases, including The Cancer Genome Atlas (TCGA), the TISIDB database, and Tumor Immune Estimate Resource (TIMER). The results were further investigated using real-time quantitative PCR (qPCR) cytology specimens in 489 patients. Furthermore, Kaplan-Meier Cox regression and prognostic nomogram analyses were used to assess FLT3LG's clinical significance in cervical cancer patients. All calculations used the R package.

Results: As a result, FLT3LG expression decreased in cervical cancer compared with standard samples. And the low expression of FLT3LG was associated with a poor prognosis. Furthermore, Receiver Operating Characteristics (ROC) analysis indicated that FLT3LG might serve as a valuable diagnostic biomarker for cervical cancer. Additionally, it indicated that the FLT3LG had the highest odds ratio (OR=10.519; (7.371-27.071)) for detecting CIN 2+. In addition, our result also demonstrated that expression of FLT3LG was closely related to immune cells, immune inhibitors, immunostimulators, receptors, and chemokines in CESC.

Conclusion: Research on FLT3LG provided insight into its critical function. Hence, the low expression of FLT3LG may be a valuable biomarker in CESC patients linked with immune infiltration.

Citing Articles

The causal relationships between inflammatory cytokines, blood metabolites, and thyroid cancer: a two-step Mendelian randomization analysis.

Liu W, Sun Y, Zhang Y, Yin D Discov Oncol. 2025; 16(1):301.

PMID: 40072746 PMC: 11904021. DOI: 10.1007/s12672-025-02029-w.

Analysis of the progression of cervical cancer in a low-and-middle-income country: From pre-malignancy to invasive disease.

Robinson E, Rodriguez I, Argueta V, Xie Y, Lou H, Milano R Tumour Virus Res. 2024; 19():200299.

PMID: 39672307 PMC: 11729683. DOI: 10.1016/j.tvr.2024.200299.

Association between immune cell attributes, serum metabolites, inflammatory protein factors, and colorectal cancer: A Mendelian randomization study.

Zhang J, Chen H, Yang R, Tang J, Yu X, Zeng P Medicine (Baltimore). 2024; 103(48):e40691.

PMID: 39612465 PMC: 11608676. DOI: 10.1097/MD.0000000000040691.

High FLT3 expression increases immune-cell infiltration in the tumor microenvironment and correlates with prolonged disease-free survival in patients with non-small cell lung cancer.

Kuncman L, Orzechowska M, Milecki T, Kucharz J, Fijuth J Mol Oncol. 2024; 18(5):1316-1326.

PMID: 38327131 PMC: 11076988. DOI: 10.1002/1878-0261.13597.

Identification of potential biomarkers and therapeutic targets related to post-traumatic stress disorder due to traumatic brain injury.

Qi P, Huang M, Ren X, Zhai Y, Qiu C, Zhu H Eur J Med Res. 2024; 29(1):44.

PMID: 38212778 PMC: 10782540. DOI: 10.1186/s40001-024-01640-x.

References

Martinez M, Moon E . CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol. 2019; 10:128. PMC: 6370640. DOI: 10.3389/fimmu.2019.00128. View

Montaldo E, Vacca P, Moretta L, Mingari M . Development of human natural killer cells and other innate lymphoid cells. Semin Immunol. 2014; 26(2):107-13. DOI: 10.1016/j.smim.2014.01.006. View

Alley E, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B . Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017; 18(5):623-630. DOI: 10.1016/S1470-2045(17)30169-9. View

Borcoman E, Le Tourneau C . Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer. Ann Transl Med. 2021; 8(23):1611. PMC: 7791256. DOI: 10.21037/atm-20-2656. View

Fokdal L, Sturdza A, Mazeron R, Haie-Meder C, Tan L, Gillham C . Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. Radiother Oncol. 2016; 120(3):434-440. DOI: 10.1016/j.radonc.2016.03.020. View

Zhang D, Qiu X, Li J, Zheng S, Li L, Zhao H . TGF-β secreted by tumor-associated macrophages promotes proliferation and invasion of colorectal cancer via miR-34a-VEGF axis. Cell Cycle. 2018; 17(24):2766-2778. PMC: 6343734. DOI: 10.1080/15384101.2018.1556064. View

Chen L, Dong B, Zhang Q, Mao X, Lin W, Ruan G . HR-HPV viral load quality detection provide more accurate prediction for residual lesions after treatment: a prospective cohort study in patients with high-grade squamous lesions or worse. Med Oncol. 2020; 37(5):37. DOI: 10.1007/s12032-020-01363-z. View

Kalanxhi E, Meltzer S, Schou J, Larsen F, Dueland S, Flatmark K . Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. Br J Cancer. 2018; 118(10):1322-1328. PMC: 5959927. DOI: 10.1038/s41416-018-0085-y. View

Rosen V, Guerra I, McCormack M, Nogueira-Rodrigues A, Sasse A, Munk V . Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer. Int J Gynecol Cancer. 2017; 27(6):1237-1246. PMC: 5499964. DOI: 10.1097/IGC.0000000000001000. View

10.

Rotman J, den Otter L, Bleeker M, Samuels S, Heeren A, Roemer M . PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential. Front Immunol. 2021; 11:596825. PMC: 7793653. DOI: 10.3389/fimmu.2020.596825. View

11.

Bruno A, Bassani B, DUrso D, Pitaku I, Cassinotti E, Pelosi G . Angiogenin and the MMP9-TIMP2 axis are up-regulated in proangiogenic, decidual NK-like cells from patients with colorectal cancer. FASEB J. 2018; 32(10):5365-5377. DOI: 10.1096/fj.201701103R. View

12.

Su C, Jia S, Liu H . Immunolocalization of CD163+ Tumor-Associated Macrophages and Symmetric Proliferation of Ki-67 as Biomarkers to Differentiate New Different Grades of Laryngeal Dysplasia. Am J Clin Pathol. 2017; 149(1):8-16. DOI: 10.1093/ajcp/aqx107. View

13.

Hammerich L, Marron T, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S . Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019; 25(5):814-824. DOI: 10.1038/s41591-019-0410-x. View

14.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

15.

Barry K, Hsu J, Broz M, Cueto F, Binnewies M, Combes A . A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018; 24(8):1178-1191. PMC: 6475503. DOI: 10.1038/s41591-018-0085-8. View

16.

Duranti S, Pietragalla A, Daniele G, Nero C, Ciccarone F, Scambia G . Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data. Cancers (Basel). 2021; 13(9). PMC: 8123488. DOI: 10.3390/cancers13092089. View

17.

Klauschen F, Muller K, Binder A, Bockmayr M, Hagele M, Seegerer P . Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. Semin Cancer Biol. 2018; 52(Pt 2):151-157. DOI: 10.1016/j.semcancer.2018.07.001. View

18.

Maraskovsky E, Brasel K, Teepe M, Roux E, Lyman S, Shortman K . Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 1996; 184(5):1953-62. PMC: 2192888. DOI: 10.1084/jem.184.5.1953. View

19.

Song W, Mazzieri R, Yang T, Gobe G . Translational Significance for Tumor Metastasis of Tumor-Associated Macrophages and Epithelial-Mesenchymal Transition. Front Immunol. 2017; 8:1106. PMC: 5601389. DOI: 10.3389/fimmu.2017.01106. View

20.

Anandasabapathy N, Feder R, Mollah S, Tse S, Paula Longhi M, Mehandru S . Classical Flt3L-dependent dendritic cells control immunity to protein vaccine. J Exp Med. 2014; 211(9):1875-91. PMC: 4144735. DOI: 10.1084/jem.20131397. View